ライフサイエンスコーパス: invasive candidiasis

1 nt of this class of antifungal drug to treat invasive candidiasis.

2 ntibodies, remain nonetheless susceptible to invasive candidiasis.

3 ol measurement may help to promptly diagnose invasive candidiasis.

4 in B and itraconazole were studied in murine invasive candidiasis.

5 nts died, and 22 (1.5%) exhibited documented invasive candidiasis.

6 y treatment and prevention of candidemia and invasive candidiasis.

7 potential as biomarkers for anticipation of invasive candidiasis.

8 ION: The primary outcomes were mortality and invasive candidiasis.

9 opment of a useful tool for the diagnosis of invasive candidiasis.

10 oint was hospital mortality or occurrence of invasive candidiasis.

11 o culture conversion in patients with proven invasive candidiasis.

12 lower incidence of the composite of death or invasive candidiasis.

13 ) immunity underlie deep dermatophytosis and invasive candidiasis.

14 eveloped and approved for treatment of human invasive candidiasis.

15 persistent, although relatively low rate of invasive candidiasis.

16 s are being used increasingly as therapy for invasive candidiasis.

17 ninferior to fluconazole in the treatment of invasive candidiasis.

18 blind, noninferiority trial of treatment for invasive candidiasis.

19 in is being used increasingly as therapy for invasive candidiasis.

20 to be efficacious in treating candidemia and invasive candidiasis.

21 n percent of the target population will have invasive candidiasis.

22 treatment regimen may improve the outcome of invasive candidiasis.

23 n treatment and prevention of candidemia and invasive candidiasis.

24 a promising candidate for the prevention of invasive candidiasis.

25 were independently significant predictors of invasive candidiasis.

26 of invasive fungal infections, particularly invasive candidiasis, after liver transplantation is str

27 We present a case report of invasive candidiasis and candidemia due to a Candida gla

28 ng-term follow-up and a detailed analysis of invasive candidiasis and candidiasis-related death in 30

29 nt, tests will also be useful for ruling out invasive candidiasis and discontinuing unnecessary antif

30 rtality from 44.0% to 30.4% in patients with invasive candidiasis and from 22.4% to 21.0% in the over

31 rophylactic fluconazole reduces the rates of invasive candidiasis and/or colonization of extremely-lo

32 , 91%, and 96% of patients were free of IFD, invasive candidiasis, and invasive aspergillosis at 1 ye

33 As an example, in the treatment of invasive candidiasis, antifungal therapy with intravenou

34 ical treatment based on surrogate markers of invasive candidiasis are warranted.

35 th Staphylococcus aureus bacteremia also had invasive candidiasis, based on histological findings in

36 oint was the incidence of proven or probable invasive candidiasis by EORTC/MSG criteria in patients w

37 Blood cultures are limited for diagnosing invasive candidiasis by poor sensitivity and slow turn-a

38 Although a rare cause of invasive candidiasis, Candida guilliermondii has been re

39 osis, and C. krusei) account for over 95% of invasive candidiasis cases.

40 Seven cases of invasive candidiasis caused by C. glabrata occurred in H

41 uman fungal pathogen Candida albicans causes invasive candidiasis, characterized by fatal organ failu

42 ents with suspected IFI was the diagnosis of invasive candidiasis confirmed.

43 greement with findings in the mouse model of invasive candidiasis, cph1/cph1 and efg1/efg1 C. albican

44 for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosa

45 For low prevalences of invasive candidiasis, culture-based fluconazole is reaso

46 inocandins are the recommended treatment for invasive candidiasis due to Candida glabrata.

47 mold infections, invasive aspergillosis, and invasive candidiasis during the first year after allogen

48 critically ill adults with risk factors for invasive candidiasis, empirical fluconazole did not clea

49 ole therapy is reasonable for likelihoods of invasive candidiasis greater than 2.5% or fluconazole re

50 tol concentrations in urine of patients with invasive candidiasis (>220 muM).

51 reased risk of mortality or of occurrence of invasive candidiasis (hazard ratio, 1.05; 95% confidence

52 for intra-abdominal infection are at risk of invasive candidiasis (IC) and candidates for preemptive

53 We characterized isolates from patients with invasive candidiasis (IC) breaking through >or=3 doses o

54 Delayed antifungal therapy for invasive candidiasis (IC) contributes to poor outcomes.

55 Rates of invasive candidiasis (IC) in children between 2003 and 2

56 Invasive candidiasis (IC) is an important cause of sepsi

57 Invasive candidiasis (IC) is an important healthcare-rel

58 Invasive candidiasis (IC) is associated with significant

59 sensitivity of blood cultures for diagnosing invasive candidiasis (IC) is poor.

60 Neonatal invasive candidiasis (IC) presenting in the first week o

61 glucan (BG) levels with clinical outcomes in invasive candidiasis (IC) remains unknown.

62 infected with C. kefyr, with 8 (9.6%) having invasive candidiasis (IC).

63 (1,3)-beta-D-glucan (BG) is a biomarker for invasive candidiasis (IC).

64 gnostic strategies are needed for diagnosing invasive candidiasis (IC).

65 le is recommended as first-line treatment in invasive candidiasis in children and infants.

66 ents to treat candidaemia and other forms of invasive candidiasis in human patients.

67 s, it has been considered as an indicator of invasive candidiasis in immunocompromised patients.

68 r the spectrum, risk factors, and outcome of invasive candidiasis in liver transplant recipients have

69 d and Drug Administration for prophylaxis of invasive candidiasis in patients undergoing bone marrow

70 Invasive candidiasis in premature infants causes death a

71 The incidence of proven/probable invasive candidiasis in the placebo and caspofungin arms

72 y means of a previously established model of invasive candidiasis in Toll mutant flies.

73 d mortality of fungal infections, especially invasive candidiasis, in patients in the intensive care

74 Some important advances in the diagnosis of invasive candidiasis include rapid species identificatio

75 CMC, invasive candidiasis, invasive aspergillosis, deep derma

76 Invasive candidiasis is a problem associated with substa

77 Invasive candidiasis is a serious infection in hospitali

78 ence of Candida albicans in a mouse model of invasive candidiasis is dependent on the phospholipids p

79 Mortality from invasive candidiasis is high.

80 Reduction in the incidence of invasive candidiasis is observed even when prophylaxis i

81 Invasive candidiasis is the most common severe fungal in

82 Invasive candidiasis is the third most common bloodstrea

83 Species should be identified for invasive candidiasis isolates, and species-level identif

84 though candidemia is not always found during invasive candidiasis, it has been considered as an indic

85 Secondary and safety outcomes included invasive candidiasis, liver function, bacterial infectio

86 Centers with a low incidence of invasive candidiasis may not benefit from fluconazole pr

87 Documented invasive candidiasis occurred in 5% of fluconazole recip

88 Invasive candidiasis occurred less frequently in the flu

89 Invasive candidiasis occurs in the gastrointestinal trac

90 Tissue from 25 autopsy patients with invasive candidiasis of the gastrointestinal tract was s

91 , a significant decrease in the incidence of invasive candidiasis (P=0.015), and an insignificant inc

92 as initial therapy in unstable patients with invasive candidiasis, particularly in the setting of pri

93 a composite of death or definite or probable invasive candidiasis prior to study day 49 (1 week after

94 dose-dependent activity in a mouse model of invasive candidiasis, reducing kidney burden by three lo

95 of studies of caspofungin in candidaemia and invasive candidiasis suggest equivalent efficacy to amph

96 rkers that assess a patient's risk of having invasive candidiasis, tests will facilitate preemptive a

97 In treatment of murine invasive candidiasis, the concomitant or sequential use

98 the composite primary end point of death or invasive candidiasis was 16% (95% CI, 11%-22%) vs 21% in

99 sensitivity of a positive BG for identifying invasive candidiasis was 87%, with a 73% specificity.

100 The overall incidence of invasive candidiasis was increased in patients who recei

101 ll-validated pharmacodynamic murine model of invasive candidiasis, we defined the effect of the combi

102 e design of qPCR for the detection of deeply invasive candidiasis, we sought to develop a more compre

103 ive value, and negative predictive value for invasive candidiasis were 74%, 75%, 62%, and 84% in the

104 Patients who had invasive candidiasis were allowed to break the blind and

105 Five episodes of proven invasive candidiasis were documented in 4 patients; 1 of

106 consecutive liver transplant recipients with invasive candidiasis were prospectively studied in a cas

107 Adults with invasive candidiasis were randomly assigned to receive e

108 s intubated for at least 5 days, and free of invasive candidiasis, were included.

109 s safe and tended to reduce the incidence of invasive candidiasis when used for prophylaxis, but the

110 e tests are limited by the low prevalence of invasive candidiasis, which mandates that results be int

111 The current standard of treatment of invasive candidiasis with echinocandins requires once-da